• letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Alaric DeArment From: medcitynews.com The company said it had shipped the first batch of the vaccine, mRNA-1273, for the NIH-run clinical trial. The study has an estimated start date of March 6, according to ClinicalTrials.gov, while The Wall Street Journal reported it would start in April. A biotech company that is one of several developing vaccines and drugs for ...
    The post Moderna ships first batch of COVID-19 vaccine for Phase I trial; study page posted online appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Kristie L. Kahl From: curetoday.com Older breast cancer survivors experienced a higher level of actionable symptoms and greater loss of well-being over time, highlighting the need for surveillance and intervention, according to findings from a study published in Cancer. “Many of the nearly 4 million US breast cancer survivors report one or more symptoms commonly associated with cancer, including ...
    The post Symptom Burden in Older Breast Cancer Survivors Highlights Need for Surveillance appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    Source: GlobalData From: prnewswire.com  China-based Qilu Pharmaceutical received approval in December 2019 for QL-1101 under the trade name Ankada, a biosimilar to Avastin (bevacizumab), to treat advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). Being the first approved Avastin biosimilar in China, Ankada will have the first-mover advantage, however its success will depend on a strong commercialization ...
    The post Qilu’s first Avastin biosimilar Ankada needs strong commercialization strategy in China, says GlobalData appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    From: PR Newswire Study identifying mechanism that prevents cell death may guide future immunotherapy strategies Some cancer cells refuse to die, even in the face of powerful cellular immunotherapies like CAR T cell therapy, and new research from the Abramson Cancer Center of the University of Pennsylvania is shedding light on why. In a new study, researchers describe how a ...
    The post Penn Researchers Identify Cancer Cell Defect Driving Resistance to CAR T Cell Therapy appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    Source: Patient Power From: prnewswire.com Patient Power®, which delivers patient-powered journalism, information and opportunities to engage with and connect to the cancer community, reports that results from the first Patient Power Cancer Clinical Trials Survey show that the majority of patients surveyed were interested in taking part in clinical trials, which is good news for drug developers and government looking ...
    The post Patient Power® Cancer Patient Survey Shows Majority of Patients Willing to Participate in Clinical Trials and Find Them Beneficial appeared first on Let Life Happen.

  • letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Hannah Slater From: cancernetwork.com Statistically significant distinctions between survival rates of patients with single hormone receptor-positive breast cancer (BC) versus double hormone receptor-positive/double hormone receptor-negative BC were observed in this study published in JAMA Network Open.1 These results suggest that different approaches might be necessary for patients with single hormone-receptor positive tumors to guarantee optimal treatment and maximum benefits from ...
    The post Different Strategies May Be Necessary for Single Hormone Receptor-Positive Breast Cancer appeared first on Let Life Happen.